New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF),…
Coronavirus: A Message From ABC President Michelle A. Albert, MD, MPH Dear Friends and Colleagues, At this time in our global history, we are severely challenged by the ongoing COVID-19/coronavirus pandemic while concurrently inspired by how different communities are pulling together at individual, leadership, medical, scientific and public health levels to mitigate this pandemic. At…
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients – – NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism – – Fills an Unmet Need for Affordable Medicines for Millions of Patients with ASCVD or HeFH – – NEXLETOL will be Commercially Available in the U.S. March 30, 2020 – – Conference…
WASHINGTON D.C. — The Association of Black Cardiologists (ABC) is pleased to support the Black Maternal Health Momnibus – composed of nine individual bills and introduced by Congresswoman Lauren Underwood, Congresswoman Alma Adams, Senator Kamala Harris, and members of the Black Maternal Health Caucus Members. “Pregnancy is said to be a “window to future health,”…
Washington, DC, February 28, 2020 – As part of its mission to promote the prevention and treatment of cardiovascular disease, including stroke, in Blacks and other minorities, the Association of Black Cardiologists (ABC) is pleased to announce our commitment to the National Hypertension Control Roundtable® (NHCR) as a founding member. The NHCR is…
– NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins – – First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved – – Esperion’s Second Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. Following NEXLETOL™ (bempedoic acid) Tablet Approval on February 21, 2020 – – Further Underscores…